Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib as first-line treatment in unresectable HCC, based on data from the randomized, open-label, international phase 3 CARES-310 trial.

Related Keywords

Minnesota ,United States ,Amit Mahipal ,Gi Oncology Program ,University Hospitals In Rochester ,Case Western Reserve University ,University Hospitals ,Camrelizumab ,Rivoceranib ,Sorafenib ,Unresectable Hepatocellular Carcinoma Hcc ,D ,Phase 3 Cares 310 Trial ,